MX2022011173A - Tratamiento de infeccion por coronavirus. - Google Patents
Tratamiento de infeccion por coronavirus.Info
- Publication number
- MX2022011173A MX2022011173A MX2022011173A MX2022011173A MX2022011173A MX 2022011173 A MX2022011173 A MX 2022011173A MX 2022011173 A MX2022011173 A MX 2022011173A MX 2022011173 A MX2022011173 A MX 2022011173A MX 2022011173 A MX2022011173 A MX 2022011173A
- Authority
- MX
- Mexico
- Prior art keywords
- coronaviruses
- coronavirus infection
- treatment
- cov
- medicaments
- Prior art date
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- CAOTVXGYTWCKQE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)-1-adamantanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 CAOTVXGYTWCKQE-UHFFFAOYSA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción se relaciona generalmente con los campos de la virología, enfermedad infecciosa y medicina y describe compuestos, composiciones, métodos y kits para el tratamiento de la enfermedad mediada por CoV, por ejemplo, una causada por SARS-CoV-2, SAR8 o MERS. Más específicamente, la divulgación se relaciona con inhibidores efectivos de los coronavirus, que pueden tratar los coronavirus que incluyen el nuevo coronavirus de 2019. En una modalidad, la divulgación proporciona un nuevo uso de WX-671 como un inhibidor efectivo de los coronavirus y su aplicación en la preparación de medicamentos para tratar la infección por coronavirus en seres humanos. En una modalidad, la divulgación proporciona un nuevo uso de ABC294640 como un inhibidor efectivo de los coronavirus y su aplicación en la preparación de medicamentos para tratar la infección por coronavirus en seres humanos.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987429P | 2020-03-10 | 2020-03-10 | |
| US202063003601P | 2020-04-01 | 2020-04-01 | |
| US202063034817P | 2020-06-04 | 2020-06-04 | |
| US202063074799P | 2020-09-04 | 2020-09-04 | |
| US202063125427P | 2020-12-15 | 2020-12-15 | |
| PCT/IB2021/000131 WO2021181157A1 (en) | 2020-03-10 | 2021-03-08 | Treatment of coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011173A true MX2022011173A (es) | 2022-10-18 |
Family
ID=76548186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011173A MX2022011173A (es) | 2020-03-10 | 2021-03-08 | Tratamiento de infeccion por coronavirus. |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11045453B1 (es) |
| EP (1) | EP4117630A4 (es) |
| JP (1) | JP2023517920A (es) |
| KR (1) | KR20220151613A (es) |
| CN (2) | CN115515560B (es) |
| AU (1) | AU2021235304A1 (es) |
| BR (1) | BR112022017923A2 (es) |
| CA (1) | CA3174438A1 (es) |
| IL (1) | IL295658A (es) |
| MX (1) | MX2022011173A (es) |
| WO (1) | WO2021181157A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
| WO2021181157A1 (en) * | 2020-03-10 | 2021-09-16 | Redhill Biopharma Ltd. | Treatment of coronavirus infection |
| US11471448B2 (en) * | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN113398219A (zh) * | 2021-06-30 | 2021-09-17 | 广州白云山星群(药业)股份有限公司 | 橘红痰咳浸膏在制备抑制人冠状病毒感染的药物中的用途 |
| EP4286851A1 (en) | 2022-06-01 | 2023-12-06 | Universität Wien | Methods and means for molecular characterization of post-viral fatigue syndrome |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342018B2 (en) | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| DE59903981D1 (de) | 1998-07-20 | 2003-02-13 | Wilex Ag | Neue urokinase-inhibitoren |
| EP1114024B1 (de) | 1998-09-18 | 2002-11-27 | Pentapharm A.G. | Urokinase-inhibitoren |
| US6861435B2 (en) | 2001-03-21 | 2005-03-01 | Pentapharm Ag | Urokinase inhibitors |
| CH695999A5 (de) | 2002-02-28 | 2006-11-15 | Wilex Ag | Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten. |
| AU2003253326A1 (en) | 2002-07-25 | 2004-02-16 | Wilex Ag | Method for the production of phenylalanine derivatives |
| DE10238048A1 (de) | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur Herstellung von Phenylalanin-Derivaten |
| US9770349B2 (en) * | 2002-11-13 | 2017-09-26 | University Of Virginia Patent Foundation | Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation |
| DE10323898A1 (de) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| GB0420874D0 (en) | 2004-09-20 | 2004-10-20 | Swetree Technologies Ab | Modulation of flowering time and growth cessation in perennial plants |
| DE102004045720A1 (de) | 2004-09-21 | 2006-03-23 | Wilex Ag | Stabile Dosierungsform von Phenylalanin-Derivaten |
| EP1799665B1 (de) | 2004-10-14 | 2009-08-19 | Wilex AG | Verfahren zur reinigung von 3-hydroxy-amidino-phenylalanin-derivaten durch ausfällung und umkristallisation eines salzes mit einer aromatischen sulfonsäure |
| DE102004057195A1 (de) | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US8324237B2 (en) | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| EP2314574A1 (en) | 2005-06-17 | 2011-04-27 | Apogee Biothechnology Corporation | Sphingosine kinase inhibitors |
| WO2012166859A2 (en) * | 2011-06-01 | 2012-12-06 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
| WO2015161908A1 (en) * | 2014-03-11 | 2015-10-29 | Ludwig-Maximilians-Universität München | Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections |
| BR112017008220A2 (pt) * | 2014-10-24 | 2018-01-09 | Redhill Biopharma Ltd. | terapia para inibição de replicação do vírus de rna de filamento único |
| EP3297438B1 (en) * | 2015-05-21 | 2021-10-20 | ChemoCentryx, Inc. | Ccr2 modulators |
| MX2018004309A (es) * | 2015-10-06 | 2018-05-22 | Redhill Biopharma Ltd | Terapias combinadas para tratar el cancer. |
| US10195188B2 (en) * | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10251888B2 (en) * | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| WO2021181157A1 (en) * | 2020-03-10 | 2021-09-16 | Redhill Biopharma Ltd. | Treatment of coronavirus infection |
-
2021
- 2021-03-08 WO PCT/IB2021/000131 patent/WO2021181157A1/en unknown
- 2021-03-08 IL IL295658A patent/IL295658A/en unknown
- 2021-03-08 JP JP2022554382A patent/JP2023517920A/ja active Pending
- 2021-03-08 US US17/195,333 patent/US11045453B1/en active Active
- 2021-03-08 KR KR1020227029182A patent/KR20220151613A/ko unknown
- 2021-03-08 CA CA3174438A patent/CA3174438A1/en active Pending
- 2021-03-08 MX MX2022011173A patent/MX2022011173A/es unknown
- 2021-03-08 CN CN202180022144.5A patent/CN115515560B/zh active Active
- 2021-03-08 CN CN202311591091.6A patent/CN117695284A/zh active Pending
- 2021-03-08 AU AU2021235304A patent/AU2021235304A1/en active Pending
- 2021-03-08 EP EP21768527.0A patent/EP4117630A4/en active Pending
- 2021-03-08 BR BR112022017923A patent/BR112022017923A2/pt unknown
- 2021-03-08 US US17/195,279 patent/US11052073B1/en active Active
- 2021-06-10 US US17/344,430 patent/US11918560B2/en active Active
- 2021-06-30 US US17/364,386 patent/US20210322390A1/en active Pending
- 2021-10-15 US US17/502,932 patent/US11364227B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210322390A1 (en) | 2021-10-21 |
| AU2021235304A1 (en) | 2022-10-06 |
| JP2023517920A (ja) | 2023-04-27 |
| US11364227B2 (en) | 2022-06-21 |
| US11045453B1 (en) | 2021-06-29 |
| US11052073B1 (en) | 2021-07-06 |
| WO2021181157A1 (en) | 2021-09-16 |
| BR112022017923A2 (pt) | 2022-10-18 |
| US20210299108A1 (en) | 2021-09-30 |
| EP4117630A4 (en) | 2024-07-03 |
| IL295658A (en) | 2022-10-01 |
| CA3174438A1 (en) | 2021-09-16 |
| US11918560B2 (en) | 2024-03-05 |
| US20220031682A1 (en) | 2022-02-03 |
| KR20220151613A (ko) | 2022-11-15 |
| CN117695284A (zh) | 2024-03-15 |
| CN115515560B (zh) | 2023-12-15 |
| EP4117630A1 (en) | 2023-01-18 |
| CN115515560A (zh) | 2022-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011173A (es) | Tratamiento de infeccion por coronavirus. | |
| MY196455A (en) | Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection | |
| MX2022012714A (es) | Inhibidores de la replicacion de norovirus y coronavirus. | |
| MX2022013270A (es) | Aplicacion antiviral de analogo de nucleosido o formulacion combinada que contiene analogo de nucleosido. | |
| MX2018015516A (es) | Inhibidores de papd5 y papd7 para tratar la infeccion por hepatitis b. | |
| BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
| BR112023025358A2 (pt) | Inibidores de protease como antivirais | |
| BRPI0518222A (pt) | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos | |
| BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
| BRPI0618374A2 (pt) | uso de um composto ou um derivado do mesmo farmaceuticamente aceitável, métodos para matar microorganismos clinicamente latentes em um mamìfero, para tratar ou prevenir uma infecção microbiana em um mamìfero, para esterilizar um objeto, para preservar um material inorgánico ou orgánico, para tratar uma doença, para reduzir a dose de agente antimicrobiano convencional requerida para tratar uma infecção microbiana e para tratar uma doença de protozoário em um mamìfero, produto combinado, formulação, uso de um produto combinado, composto, e, processo para a preparação do mesmo | |
| TW200733953A (en) | Materials and methods for treating viral infections | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| ATE444749T1 (de) | Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| MX2023013538A (es) | Metodos para tratar la depresion y la ansiedad. | |
| MX2023013536A (es) | Metodos para tratar la depresion y la ansiedad. | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| AR123281A1 (es) | Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9 | |
| BR112022013480A2 (pt) | Métodos de tratamento de coronavírus | |
| BRPI0510451A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização | |
| BR112021023347A2 (pt) | Compostos de pirrolidina | |
| BR112021018724A8 (pt) | "inibidores de pi4-cinase e métodos de usar os mesmos | |
| BR112023016958A2 (pt) | Compostos para uso no tratamento de uma infecção por vírus envelopado |